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Abstract
Introduction: Emerging antituberculosis drug resistance is a serious threat for tuberculosis (TB) control, especially in Eastern
European countries.
Methods: We combined drug susceptibility results and molecular strain typing data with treatment outcome reports to
assess the influence of drug resistance on TB treatment outcomes in a prospective cohort of patients from Abkhazia
(Georgia). Patients received individualized treatment regimens based on drug susceptibility testing (DST) results. Definitions
for antituberculosis drug resistance and treatment outcomes were in line with current WHO recommendations. First and
second line DST, and molecular typing were performed in a supranational laboratory for Mycobacterium tuberculosis (MTB)
strains from consecutive sputum smear-positive TB patients at baseline and during treatment.
Results: At baseline, MTB strains were fully drug-susceptible in 189/326 (58.0%) of patients. Resistance to at least H or R
(PDR-TB) and multidrug-resistance (MDR-TB) were found in 69/326 (21.2%) and 68/326 (20.9%) of strains, respectively. Three
MDR-TB strains were also extensively resistant (XDR-TB). During treatment, 3/189 (1.6%) fully susceptible patients at baseline
were re-infected with a MDR-TB strain and 2/58 (3.4%) PDR-TB patients became MDR-TB due to resistance amplification. 5/
47 (10.6%) MDR- patients became XDR-TB during treatment. Treatment success was observed in 161/189 (85.2%), 54/69
(78.3%) and 22/68 (32.3%) of patients with fully drug susceptible, PDR- and MDR-TB, respectively. Development of ofloxacin
resistance was significantly associated with a negative treatment outcome.
Conclusion: In Abkhazia, a region with high prevalence of drug resistant TB, the use of individualized MDR-TB treatment
regimens resulted in poor treatment outcomes and XDR-TB amplification. Nosocomial transmission of MDR-TB emphasizes
the importance of infection control in hospitals.
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Introduction
Antituberculosis drug resistance is a serious threat to the
achievement of the goal of the Stop TB partnership to eliminate
tuberculosis (TB) as a public health problem by 2050 [1].
Multidrug-resistance (MDR-TB) is defined as resistance to isoniazid
(H) and rifampicin (R). Extensive drug-resistance (XDR-TB) is
defined as MDR-TB plus resistance to a fluoroquinolone and any
one of the second-line injectable drugs (capreomycin, amikacin or
kanamycin). The World Health Organization (WHO), estimated a
total number of 440,000 cases and 150,000 deaths due to MDR-TB
in the year 2008 [2]. A recent investigation showed that up to 15%
of MDR-TB strains worldwide are already XDR-TB [3].
Current guidelines for drug resistant TB management are based
on expert opinion and case series. Furthermore, there are very few
reports on treatment outcomes of regimens for mono- or poly-drug
resistant TB. Overall, MDR-TB is associated with much poorer
treatment outcomes compared with drug susceptible TB [4–8].
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which result in enhanced transmission of drug resistant Mycobac-
terium tuberculosis (MTB) strains [9].
Treatment of MDR-TB patients appears to entail a consider-
able risk of creating XDR-TB with the potential of direct
transmission of XDR-TB strains [10]. Reasons for resistance
amplification in MDR-TB cases on individualised second line
treatment regimen urgently require further systematic investiga-
tion [11].
MTB drug resistance is particularly prevalent in Eastern part of
Europe or in Central Asia, where 12 countries have reported
proportions of MDR-TB rates of 6% or more among new TB
cases [2]. In such scenarios of highly prevalent MTB drug
resistance, current recommendations include systematically per-
forming drug susceptibility testing (DST) at the time of TB
diagnosis, initiating standardized short course chemotherapy until
DST results are available and adapting treatment in case drug
resistance is found [12]. This treatment strategy was introduced
in 2001 by Me ´decins Sans Frontie `res (MSF) in Abkhazia, an
autonomous region of western Georgia with an estimated popula-
tion of 150,000 inhabitants. The TB incidence was 84/100,000
inhabitants in 2008 and more than 8% of new cases were
identified as MDR-TB [13,14]. Approximately 20% of MTB
strains harbour the specific phylogenetic lineage Beijing genotype
that was identified as an independent risk factor of MDR-TB and
MTB transmission, indicating a potential role of strains with
Beijing genotype in the epidemiology of the drug resistant TB
(DR-TB) in the region [15,16].
We performed an in depth investigation of the effectiveness of
the TB treatment strategy in Abkhazia. Working within an existing
prospective cohort, we combined DST results, molecular strain
typing data and reports of treatment outcomes to identify
predictors of negative treatment outcomes and to describe DR-
TB amplification and re-infection during treatment.
Methods
Study design and population
Following informed consent, all patients aged $18 years old
with sputum smear-positive pulmonary TB, presenting to the
Gulripsch TB referral centre in Abkhazia (Georgia), were enrolled
between March 2003 and September 2005 in a prospective cohort
study. Due to the chronic conflict situation with Georgia since
1994, the Abkhazia TB control program has limited connection
with the national TB program of Georgia. The program has
received support from Me ´decins Sans Frontie `res for diagnosis and
treatment of all TB cases since 1999.
Treatment strategy and patient follow-up
TB screening was performed based on clinical symptoms, chest
X-ray and sputum smear microscopy examination. TB case defi-
nitions followed WHO/IUATLD guidelines [12,17]. All patients
were started on empirical standard short course chemotherapy with
H, R, pyrazinamide (Z) and ethambutol (E). Streptomycin (S) was
added for patients with a previous TB treatment history. Treatment
was then adapted according to DST results, as described in Table 1.
Prior to 2
nd line drug DST results, MDR-TB patients were given an
empiric MDR regimen (see Table 1). This regimen was further
adapted,accordingto2
ndline drugsDSTresults,inordertoachieve
a minimum of six months intensive phase containing at least four
2
nd line drugs to which the MTB strain was highly likely susceptible.
Clofazimine and amoxicillin-clavulanate were added to the regimen
when the number of highly likely effective 2
nd line drugs was
insufficient. The first line drugs, E and Z were continued if found
susceptible. The intensive phase lasted a minimum of 6 months and
at least 4 months after culture conversion. All non MDR-TB
patients presenting with a MTB resistance to at least H or R were
given an adapted treatment regimen (Table 1). Though this group
included mono- and poly-drug resistant TB, for the sake of
conciseness, these patients were named as PDR-TB.
The continuation phase lasted between seven and twelve months
for PDR-TB and eighteen months for MDR-TB, following com-
pletion of the intensive phase, provided patients remained con-
tinuously smear- and culture-negative throughout this period.
Patients’ response was monitored by monthly sputum smear and
culture examination. Culture was not repeated in PDR-TB patients
with smear-negative follow-up results and good clinical response.
After two months with positive culture results, PDR-TB patients
received an empirical MDR-TB regimen (Cm, FQ, Eto, PAS and
Cs) whilst waiting for DST results. Patients were hospitalized during
the entire intensive phase and had monthly outpatient visits during
the continuation phase. Blood count, liver, and renal function tests
and serum electrolytes were performed regularly. Early and
aggressive management of side effects was provided. Treatment
was delivered free of charge and under direct observation and with
strong psycho-social support during the entire course of treatment.
TheWHOGreen Light Committeeapprovedthe program in2004.
Laboratory procedures
Smear microscopy used the hot Ziehl Neelsen method. Two
sputum specimens of all smear-positive patients were sent to the
supra-national TB laboratory at the Istituto Superiore di Sanita `,
Roma (Italy) for culture and DST. Specimens were processed by
the N-acetyl-L-cysteine-NaOH (NALC) method and inoculated
into Lowenstein-Jensen (LJ) medium (Biome ´rieux, Marcy l’Etoile,
France) and BACTEC MGIT 960 (MGIT) tubes (Becton-
Dickinson), according to manufacturer’s instructions. LJ slants
were incubated at 37uCi n5 %C O 2 and controlled weekly for 8
weeks. TB strains were identified in positive cultures by DNA
probes (Gene Probe, San Diego, Ca). DST for H, R, E and S was
carried out using the MGIT system. In case of resistance to 1
st line
drugs, DST for Ofx, Km, Cm, Eto, PAS and Cs was performed
using the proportion methods on 7H10, as previously described
[15]. Isolated strains were shipped to the Research Centre Borstel
(Germany) for molecular typing. Extraction of genomic DNA from
mycobacterial strains and DNA fingerprinting, using IS6110 as a
probe, were performed according to a standardized protocol [18].
Additionally, all isolates were analyzed by the spoligotyping
technique [19]. Molecular typing data were analyzed with
Bionumerics software (version 4?5; Applied Maths, Sint-Martens-
Table 1. Treatment according to drug resistance patterns.
Resistance Intensive phase Continuation phase
S, E or ES 2 H R Z E 4 H R
MDR* $6 Cm-Ofx/Mx-Eto/Pto PAS Cs 18 Ofx/Mx Eto/Pto PAS Cs
Ho rH S 2 HRZE 7REZ
HE or HES 3 Cm/Km Ofx/Mx R Z 7 Ofx/Mx R Z
R or RS 3 Cm/Km Ofx/Mx E Z 12 Ofx/Mx E Z
RE or RES 3 Cm/Km Ofx/Mx H Z 12 Ofx/Mx H Z
E: ethambutol; S: streptomycin; H: isoniazid; MDR: multidrug resistance; Cm:
capreomycin; Km: kanamycin; Ofx: ofloxacin; Mx: moxifloxacin; Eto:
ethionamide; Pto: prothionamide; PAS: paramino salicylic acid; Cs: cycloserine.
*Empiric treatment further adapted to DST to 2nd line drugs.
doi:10.1371/journal.pone.0023081.t001
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relationships and for genotype classification according to SpolDB4
and the MIRU-VNTRplus webpage [19–21]. In addition, we
screened IS6110 Restriction Fragment Length Polymorphism
(RFLP) and spoligotyping patterns for mixed infections (infection
with two strains).
Definitions of treatment outcome, drug resistance
amplification and re-infection
WHO definitions of treatment outcome definitions were used
for patients susceptible to first line drugs or resistant to S, E or ES
[12,17]. For MDR-TB, a patient was defined as ‘‘cured’’ if s/he
completed the treatment and had at least five consecutive negative
culture results during the final twelve months of treatment. If only
one positive culture was reported during that time without
concomitant clinical evidence of deterioration, the patient was
still considered as being cured, provided that this positive culture
was followed by a minimum of three consecutive negative cultures,
recorded at least 30 days apart. Patient was declared as ‘‘failure’’ if
two or more of the five cultures recorded in the final twelve
months were positive, or if any one of the final three cultures was
positive, or if a clinical decision was made to discontinue treatment
early due to poor response or adverse events. For PDR-TB,
patient was defined as ‘‘cured’’ if s/he completed treatment and
had at least three consecutive negative smear/culture results
during the final six months of treatment. Patient was declared as
‘‘failure’’ if having at least one positive culture after three months
of adapted regimen.
For both MDR- and PDR-TB, ‘‘treatment completion’’ was
defined as a patient who completed treatment but did not meet the
definition for ‘‘cure’’ due to lack of bacteriological results. ‘‘Death’’
was defined by the occurrence of death during treatment
regardless of the cause and ‘‘defaulting’’ if the patient missed at
least two consecutive months of treatment. The combination of
‘‘cure’’ and ‘‘treatment completed’’ defined ‘‘success’’. Culture
conversion was reported using the latest WHO case definition of
two consecutive negative smears and cultures taken 30 days apart
[12].
Drug resistance amplification was defined as an increase in the
number of drugs towards which MTB was resistant in vitro during
treatment follow-up compared with baseline, if both baseline and
follow-up strains were genetically identical. If strains were
different, the increase in drug resistance was attributed to a re-
infection.
Statistical analysis
Clinical and laboratory data were entered into a database using
SQLServer (Microsoft Visual Studio.NET 7?0) and analyzed in
StataSE
TM,9
th version, College Station, TX. Treatment outcomes
were presented according to patients’ baseline DST patterns. For
MDR-TB patients, treatment outcomes were also presented
according to any baseline resistance to second line drugs. The
proportion of culture converted patients who reverted to culture
positivity was calculated. When tabulating proportions of patients
who became resistant during treatment, patients without complete
follow-up laboratory information were excluded from the analysis.
To calculate the drug resistance amplification and exogenous re-
infection patients with mixed or double infection were excluded.
Univariate analysis was performed to identify factors associated
with a negative outcome of MDR-TB treatment (death or failure)
among baseline patients’ characteristics (age, gender, TB treat-
ment history and prisoner history) and biological markers (DST
results and molecular findings), after exclusion of defaulters.
Because there were very few missing observations, they were
excluded from the analysis.
The study was approved by the health authorities of Abkhazia
and the Ministry of Health of Georgia.
Results
A total of 405 smear-positive pulmonary TB patients were
diagnosed in the Gulripsch hospital between March 2003 and
September 2005. Out of these, 366 (90.4%) met the inclusion
criteria. Data from 326 patients were included in the final analysis.
The 40 exclusions were: due either to shipment problems with
sputum specimen for MTB culture for 11 cases, 3 cases with
culture contamination and 26 cases with baseline negative culture
results.
Table 2 shows patients’ baseline characteristics. A total of 195
patients (59.8%) had strains resistant to at least one 1
st line drug
and 135 (41.4%) patients were at least resistant to isoniazid.
Among the 195 patients, 57 (29.3%) had strains resistant to at least
one 2
nd line drug. A total of 69 patients were PDR-TB (21.2%)
and 68 were MDR-TB (20.9%). Among PDR-TB, 2 (2.9%) were
resistance to R. Among MDR-TB cases, 3 were XDR-TB (4.5%).
The median number of drugs (1
st and 2
nd line), to which MDR-TB
patients were resistant to was 4.5 drugs, interquartile range (IQR)
[4–6]. One fourth harboured a strain belonging to the Beijing
family.
The overall treatment success rate was 72.7% (237/326),
defaulting rate 16.2% (53/326), death rate 7.7% (25/326), and
failure rate 3.4% (11/326). Table 3 shows treatment outcomes
Table 2. Baseline characteristics of patients, N=326.
Results
Sex ratio Male: Female 252:74
Age, mean (Standard Deviation) 42 (14)
Past TB treatment history n (%) 127 (39.1)
a
Former prisoner, n (%) 38 (11.7)
b
Baseline drug resistance pattern, n (%)
Fully susceptible or resistant to S, E or SE 189 (58.0)
Monoresistance to H 27 (8.3)
Resistance to HS 29 (8.9)
Resistance to EH +-S 11 (3.4)
Monoresistance to R+-S 2 (0.6)
HR+-S resistance 48 (14.7)
HRE+-S resistance 20 (6.1)
Among MDR, n (%) 68 (20.9)
c
Resistance to at least one 2
nd line drug 36 (52.9)
Resistance to ethionamide 25 (37.3)
Resistance to ofloxacin 3 (4.5)
Resistance to kanamycin and/or capreomycin 21 (31.4)
XDR 3 (4.5)
Infection with Beijing strain
d, n (%) N=311 78 (25.1)
a1 missing information.
b2 missing informations.
cOne case without DST result for all 2
nd line drugs.
dExclusion of 15 patients with mixed or double infection.
E: ethambutol; S: streptomycin; H: isoniazid; MDR: multidrug resistance; XDR:
extensively drug-resistance.
doi:10.1371/journal.pone.0023081.t002
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patients with fully drug susceptible patients, and 78.3% for
patients with PDR-TB strains. There was no statistically significant
difference in success rate between patients with full susceptible,
H+-S, or HE+-S resistant strains (p=0.67). The small number of
PDR-TB resistant to R didn’t allow comparison of outcome with
other PDR-TB.
Almost one fourth of MDR-TB patients died after a median
period of treatment of 1 month, IQR [0–7.6]. One third
discontinued treatment after a median period of 6.6 months
IQR [4–12.9].
MDR-TB treatment success rate was 41.9% (13/31) for patients
without resistance to 2
nd line drugs and 27.8% (10/36) for patients
with resistance to any 2
nd line drug. However, this difference was
non-significant (p=0.22). Out of the 3 XDR-TB patients 2 died
and 1 defaulted.
Out of 68 MDR-TB patients, 37 (54.4%) converted to culture
negative. After exclusion of 21 patients who died or defaulted
during the first 6 months of treatment, the culture conversion rate
was 78.7% (37/47). Median time to culture conversion was 6
months IQR [4–7]. Among the 37 patients who converted, 4
(10.8%) reverted to culture positive during treatment at 3 (n=2), 6
(n=1) and 8 (n=1) months after culture conversion. Of these 4
patients, 1 failed treatment, 2 died and 1 defaulted.
None of the baseline MDR-TB patients’ characteristics were
significantly associated with a negative outcome (Table 4).
Figure 1 shows patterns of drug resistance amplification and re-
infection during treatment. Three patients with fully susceptible
MTB strains were re-infected with a MDR-TB strain and had
negative outcomes despite treatment adaptation. Cluster analysis
showed that for one of them, the index case was a fellow patient
hospitalised during the same period. This cluster included the
strains from these 2 patients. Another patient was infected one
month after starting treatment with a strain belonging to a cluster
of MDR-TB strains identified in 3 other patients. They were all
hospitalised for MDR-TB treatment during the same period as the
contact case. The last patient was infected with a strain belonging
to a cluster of MDR-TB strains identified in 15 patients. Three
patients were hospitalised for MDR-TB treatment when the
contact was regularly visiting the hospital to receive ambulatory
treatment.
Among 58 PDR-TB strains of patients with complete follow-up
culture and finger printing results, 2 amplified to MDR-TB during
treatment (3.4%). 1/7 (14.3%) and 1/48 (2.1%) PDR-TB patients
were infected with a Beijing strains and with a non-Beijing strain
who amplified to MDR-TB, respectively (Fig. 1A).
Of the 47 MDR-TB patients susceptible to Ofx at baseline with
follow-up culture results, 8 developed Ofx resistance (Fig. 1B).
DNA fingerprinting was possible for 7 of these (1 culture was
contaminated) showing re-infection with a XDR-TB strain in one
patient and amplification to Ofx in 6 patients. The amplification
rate to Ofx was 13.3% (6/45). It was 3.1% (1/32) and 2.2% (1/46)
for Km and Cm, respectively. The Ofx resistance amplification
rate was higher in MDR-TB patients infected with a Beijing strain
5/29 (17.2%) compared with those infected with a non-Beijing
strain 1/16 (6.2%). However, this does not reach statistical
significance (p=0.56). Finally, of the 46 MDR-TB patients who
were not XDR-TB at baseline and had valid follow-up culture
results and RFLP results, 3 amplified to XDR TB during
treatment (6.7%) and one was re-infected with a Beijing XDR-
TB strain. The increase in Ofx resistance during treatment was
significantly associated with a negative outcome (p,0.001).
Discussion
Our study demonstrates that in a geographic area with high
MDR-TB prevalence, such as Abkhazia, a treatment strategy
based on early detection of drug resistance and treatment
adaptation can be highly successful in patients with fully drug
susceptible, mono- and poly-drug resistant strains but not in
MDR-TB patients. Less than 1% (2/228) of these patients
amplified resistance to MDR-TB on TB treatment. However,
three patients with fully susceptible strains were re-infected with an
MDR-TB strain, most likely in the TB hospital, despite infection
control measures being in place, including the separation between
susceptible, PDR and MDR-TB patients. Due to the absence of
HIV testing in this study, it was not possible to assess if the
nosocomial transmission could be explained by a high rate of TB-
HIV infection. However, this seems unlikely given the low HIV
prevalence among adults in Georgia (0.1% in 2007) [22]. The
centralisation of drug resistance treatment and the long duration of
hospitalisation of MDR-TB patients might have increased the risk
of nosocomial transmissions [23,24].
Contrary to the situation of patient with susceptible and PDR-
TB, the TB control strategy in place in Abkhazia failed to
successfully treat MDR-TB patients, despite the use of individu-
alized treatment regimens in line with international recommen-
dations. Indeed, the success rate (32%) was substantially lower
Table 3. Tuberculosis treatment outcomes according to baseline drug resistance patterns.
Full susceptible and resistant
to E, S or ES n (%) PDR* MDR n (%)
H or HS resistance n (%) HE or HES resistance n (%)
N 189 56 11 68
Positive outcome (success) 161(85.2) 45 (80.3) 9 (81.8) 22 (32.3)
Cured 154 (81.5) 42 (75) 6 (54.5) 13 (19.1)
Completed 7 (3.7) 3 (5.4) 3 (27.3) 9 (13.2)
Negative outcome 11 (5.8) 3 (5.4) 1 (9.1) 22 (32.3)
Failure 4 (2.1) 2 (3.6) 0 5 (7.3)
Death 7 (3.7) 1 (1.8) 1 (9.1) 16 (23.5)
Defaulter 17 (9) 8 (14.3) 1 (9.1) 25 (36.7)
*Two patients were also resistant to rifampicin and rifampicin + streptomycin. Both were defaulters.
E: ethambutol; S: streptomycin; H: isoniazid; PDR: polydrug resistance; MDR: multidrug resistance.
doi:10.1371/journal.pone.0023081.t003
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last published meta-analysis of 29 studies using individualized
treatment regimens [4]. Our data are more in accordance with
unpublished results from a recent meta-analysis, reporting an
average success rate of 54%, and below 50% in several high
incidence settings [25]. This last meta-analysis includes data from
published and unpublished cohorts, which can reduce the risk of
publication bias and could explain the lower success rate
compared with previous meta-analysis. One factor contributing
to the low MDR-TB treatment success rate in Abkhazia is the high
death rate (23%) [4]. Most of the deaths occurred very early after
starting treatment and could be due to late diagnosis. Since the TB
drug resistance program in Abkhazia started in 2001 and was still
new at the beginning of the study (2003), the backlog of
undiagnosed MDR-TB patients could explain why some patients
were diagnosed late in an advanced stage of the disease. The HIV-
TB co-infection rate was estimated to be low in the region and is
unlikely to contribute significantly to the high death rate observed
in our study.
The high defaulter rate also contributes to the poor treatment
success of MDR-TB patients in Abkhazia. Combinations of several
factors resulting from the difficult social and economical conditions
(chronic conflict and 10 years of economic blockade) are likely to
contribute to this problem. Despite big efforts, good hospitalisation
conditions, social support, and early management of side effects,
patients had difficulties in tolerating long hospitalisation. Earlier
discharge from hospital and decentralised treatment, which started
in 2007, may enhance treatment effectiveness through better
adherence.
Due to the small sample size of MDR-TB patients, we couldn’t
confirm the association between baseline resistance to Ofx and
negative outcomes in our study, as it had been shown in previous
studies [26,27]. The only predictor of poor outcomes in our study
was the increase to Ofx resistance during treatment. Indeed, 17%
of MDR-TB patients became resistant to Ofx. Resistance ampli-
fication could be confirmed in two third of them. Amplification to
Ofx resistance during MDR-TB treatment has already been
reported, and it can seriously jeopardise the patient’s chance to be
cured [10,28,29]. Interestingly, resistance amplification was nearly
completely restricted to Beijing genotype strains, although this
association was not statistically significant probably due to the
small numbers. In line with previous reports it might be speculated
that Beijing genotype strains have a higher capacity to develop
drug resistances in case of pre-existing resistance, resulting in a
selective advantage for Beijing genotype strains in areas with
higher levels of drug resistance [7]. This is in accordance with the
high rates of Beijing genotype strains found in several regions of
the former Soviet Union and the observed association with MDR-
TB resistance. The factors that lead to resistance amplification
under adequate treatment regimens need to be urgently identified,
in order to avoid ongoing XDR-TB development in high
incidence settings.
Table 4. Predictors of poor treatment outcomes of MDR-TB patients: univariate analysis (N=43).
Characteristics n Negative outcomes % P-value
Gender Male 5 52.6 0.20
Female 38 20.0
Age group #30 7 42.9 0.10
30–39 16 37.5
40–49 15 73.3
50 and more 5 20.0
Patient’s type* Previously Treated Cases 31 51.6 0.38
New Cases 11 36.4
Prisoner history Yes 35 62.5 0.46
No 8 45.7
Beijing strain** Yes 30 35.7 0.27
No 9 53.6
Baseline 2
nd line resistance Yes 21 52.4 0.76
No 22 45.5
Baseline resistance to Ofx* Yes 2 100 0.22
No 40 45
Baseline resistance to Km* Yes 11 54.5 0.73
No 31 45.2
Number of drugs resistant to ,4 drugs 9 33.3 0.75
4 drugs 14 57.1
5 drugs 11 45.4
$6 drugs 9 55.6
Increase of Ofx resistance* Yes 100 ,0.001
No 18.5
*Missing information.
**After exclusion of 4 cases with mixed or double infection.
Km: kanamycin; Ofx: ofloxacin.
doi:10.1371/journal.pone.0023081.t004
Tuberculosis Drug Resistance Treatment Outcomes
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23081Tuberculosis Drug Resistance Treatment Outcomes
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23081This prospective cohort gave the opportunity to evaluate the
recently established WHO case definitions for MDR-TB culture
conversion [12]. Four out of 37 patients (11%) who converted their
culture according to the WHO definition reverted to positive. The
relevance of using two consecutive negative culture results as a
definition for culture conversion to determine treatment duration
should be further examined [12,30].
In conclusion, in Abkhazia, the treatment strategy was effective
for susceptible TB and for mono- and poly-drug resistant TB but
not for MDR-TB. Ensuring adherence to long and poorly effective
treatment regimens, especially for patients living in difficult socio-
economical conditions, is a real challenge in Abkhazia. These
outcomes and particularly the amplification from MDR- to XDR-
TB plead for the development of more effective and shorter
regimens. Large multicentric cohort analyses are required to
further investigate optimal treatment regimens for MDR-TB with
existing drugs. The evidence of MDR-TB nosocomial transmission
emphasizes the paramount importance of infection control in
hospitals and of more decentralized and outpatients approaches
for treating drug resistant TB. In high MDR burden and limited
resource countries, the programmatic impact of using the new
molecular methods (eg. XpertMTB/RIFH test), which does not
require heavy laboratory infrastructure, should be assessed.
Indeed, these methods would allow faster identification of
rifampicin resistance in both smear-positive and smear-negative
patients, and a more rapid initiation of empirical MDR regimen,
while waiting for full DST results. It is likely that earlier MDR
treatment would reduce the case fatality rate and the risk of
nosocomial transmission. XpertMTB/RIFH was recently intro-
duced in the Abkhazia TB program.
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